Novartis AG released its Annual Report for 2024, alongside its ‘Novartis in Society – Integrated Report 2024.’ This announcement underscores the company ...

Novartis AG (NYSE:NVS), a global healthcare company valued at over $206 billion, has undergone significant transformation in recent years, focusing its efforts on becoming a pure-play pharmaceutical ...

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...

During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.

Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

TD Cowen analyst Steve Scala reiterated a Hold rating on Novartis (NVS – Research Report) today and set a price target of $125.00. The ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

Bank of America Securities analyst Graham Parry has maintained their neutral stance on NOVN stock, giving a Hold rating today.Invest with ...

Looking ahead to 2025, Novartis maintains an optimistic stance, forecasting mid to high single-digit sales growth and anticipating even stronger operational core earnings in the high single to low ...